Trade name: IPOL®
Generic names: Poliovirus Vaccine Inactivated
Indication and Usage: IPOL vaccine is indicated for active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Types 1, 2, and 3.
Ingredients: Each dose (0.5 mL) of trivalent vaccine is formulated to contain 40 D antigen units of Type 1, 8 D antigen units of Type 2, and 32 D antigen units of Type 3 poliovirus. For each lot of IPOL vaccine, D-antigen content is determined in vitro using the D-antigen ELISA assay. IPOL vaccine is produced from vaccine concentrates diluted with M-199 medium. Also present are 0.5% of 2- phenoxyethanol and a maximum of 0.02% of formaldehyde per dose as preservatives. Neomycin, streptomycin, and polymyxin B are used in vaccine production; and, although purification procedures eliminate measurable amounts, less than 5 ng neomycin, 200 ng streptomycin, and 25 ng polymyxin B per dose may still be present. The residual calf bovine serum albumin is less than 50 ng/dose in the final vaccine.
Manufacturer-listed adverse reactions: Inactive Polio (IPOL) can cause: Lymphadenopathy, Anaphylactic shock, Arthralgia (joint pain), Myalgia (muscle pain), Convulsion, Febrile convulsion, Headache, Paresthesia (skin crawling), Somnolence (long period of sleep), Urticaria (hives).
Need more info? Click the link below for a helpful infographic you can view + save on your device.
